Optic IconOptic Logo
|
SearchCollectionsBenchmarks

TRC105

1 product

1 abstract

1 target

Target
endoglin
Abstract
NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).
Org: Mayo Clinic, Alliance Statistics and Data Center, University of California Irvine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University of Virginia Health System,
Product
TRC105 + bevacizumab